Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Pain, Intractable 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cancer Pain 1

Interventions

Cyclophosphamide 6fludarabine 5Rituximab 4obinutuzumab 3tafasitamab 2relmacabtagene autoleucel 2pirtobrutinib 2zanubrutinib 1venetoclax 1tisagenlecleucel 1resiniferatoxin 1pomalidomide 1polatuzumab vedotin 1glofitamab 1Vincristine 1Tretinoin 1Surveys and Questionnaires 1Specimen Handling 1Radiotherapy 1Prednisolone 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1Doxorubicin 1Dexamethasone 1Blood Specimen Collection 1Bendamustine Hydrochloride 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, B-Cell × resiniferatoxin × Clear all
NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center

Phase 1 Not yet recruiting
15 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡